查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1291485

乳腺癌液體活體組織切片市場：2023-2028年全球行業趨勢、佔有率、規模、成長、機會和預測

Breast Cancer Liquid Biopsy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3個工作天內

價格

市場概述：

全球乳腺癌液體活體組織切片市場規模在2022年達到1.107億美元。展望未來，IMARC Group預計，到2028年，市場規模將達到3.262億美元，在2023-2028年期間呈現17.81%的成長率（CAGR）。

乳腺癌液體活體組織切片是指一種非侵入性的醫療程序，利用血液作為樣本來識別腫瘤標誌物。它有助於評估乳腺癌疾病的進展，檢測表皮生長因子受體（EGFR）的基因突變，幫助臨床醫生在正確的時間選擇最佳行動方案。這一過程中使用的一些常見生物標記包括循環腫瘤細胞（CTC）、細胞外囊泡、循環腫瘤DNA等。乳腺癌液體活體組織切片有幾個好處，包括最小的侵入性、新病變的特徵、癌症治療的藥物和治療目標的識別等等。

乳腺癌液體活體組織切片的市場趨勢：

乳腺癌發病率的成長以及對非侵入性醫療程序的需求升級是推動全球乳腺癌液體活體組織切片市場的主要原因。除此之外，消費者對與液體活體組織切片技術相關的眾多好處的認識不斷提高，包括更快的結果、更低的成本、最小的健康風險、非侵入性等，也促進了市場成長。此外，各種全球組織正在開展宣傳活動，對個人進行乳房健康和癌症診斷措施的教育。再加上政府和私人對乳腺癌活體組織切片和其他相關醫療程序的報銷政策越來越多，這為市場創造了一個積極的前景。除此之外，許多製造商正在對引進先進的活體組織切片技術進行大量投資，以加強乳腺癌管理的幾個方面，如預測預後、早期診斷復發、連續取樣、有效縱向監測疾病進展和對治療的反應等。此外，個性化治療的新興趨勢加上聚合酶鏈反應（PCR）和下一代測序（NGS）在癌症檢測中的廣泛採用，將在未來幾年繼續推動全球乳腺癌液體活體組織切片市場。

本報告中回答的關鍵問題：

  • 2022年全球乳腺癌液體活體組織切片市場的規模是多少？
  • 2023-2028年期間，全球乳腺癌液體活體組織切片市場的預期成長率是多少？
  • COVID-19對全球乳腺癌液體活體組織切片市場的影響是什麼？
  • 推動全球乳腺癌液體活體組織切片市場的關鍵因素是什麼？
  • 基於產品服務的全球乳腺癌液體活體組織切片市場的詳細情形是怎樣的？
  • 全球乳腺癌液體活體組織切片市場的主要地區有哪些？
  • 誰是全球乳腺癌液體活體組織切片市場的主要參與者/公司？

目錄

第一章：前言

第二章：範圍和方法

  • 研究的目標
  • 利益相關者
  • 數據來源
    • 主要來源
    • 二級來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第三章：執行摘要

第四章：簡介

  • 概述
  • 主要行業趨勢

第五章：全球乳腺癌液體活體組織切片市場

  • 市場概況
  • 市場表現
  • COVID-19的影響
  • 市場預測

第六章：按產品服務分類的市場

  • 試劑盒
    • 市場趨勢
    • 市場預測
  • 儀器
    • 市場趨勢
    • 市場預測
  • 服務業
    • 市場趨勢
    • 市場預測

第7章：循環生物標記的市場細分

  • 循環腫瘤細胞(CTCs)
    • 市場趨勢
    • 市場預測
  • 無細胞DNA (cfDNA)
    • 市場趨勢
    • 市場預測
  • 細胞外囊泡（EVs）
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第8章：按終端用戶分類的市場

  • 參考實驗室
    • 市場趨勢
    • 市場預測
  • 醫院和醫生實驗室
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第九章：按地區分類的市場

  • 北美洲
    • 美國
      • 市場趨勢
      • 市場預測
    • 加拿大
      • 市場趨勢
      • 市場預測
  • 亞太地區
    • 中國
      • 市場趨勢
      • 市場預測
    • 日本
      • 市場趨勢
      • 市場預測
    • 印度
      • 市場趨勢
      • 市場預測
    • 韓國
      • 市場趨勢
      • 市場預測
    • 澳大利亞
      • 市場趨勢
      • 市場預測
    • 印尼
      • 市場趨勢
      • 市場預測
    • 其他國家
      • 市場趨勢
      • 市場預測
  • 歐洲
    • 德國
      • 市場趨勢
      • 市場預測
    • 法國
      • 市場趨勢
      • 市場預測
    • 英國
      • 市場趨勢
      • 市場預測
    • 義大利
      • 市場趨勢
      • 市場預測
    • 西班牙
      • 市場趨勢
      • 市場預測
    • 俄羅斯
      • 市場趨勢
      • 市場預測
    • 其他國家
      • 市場趨勢
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場趨勢
      • 市場預測
    • 墨西哥
      • 市場趨勢
      • 市場預測
    • 其他國家
      • 市場趨勢
      • 市場預測
  • 中東和非洲
    • 市場趨勢
    • 按國家分類的市場
    • 市場預測

第十章：SWOT分析

  • 概述
  • 優勢
  • 劣勢
  • 機會
  • 威脅

第十一章：價值鏈分析

第十二章：波特斯五力分析

  • 概述
  • 買方的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第十三章：價格分析

第十四章：競爭格局

  • 市場結構
  • 主要參與者
  • 主要參與者的概況
    • Biocept Inc.
    • Bio-Rad Laboratories Inc.
    • F. Hoffmann-La Roche AG
    • Fluxion Biosciences Inc.
    • Guardant Health Inc.
    • Illumina Inc.
    • Menarini Silicon Biosystems (The Menarini Group)
    • NeoGenomics Laboratories Inc.
    • Qiagen
    • Sysmex Europe SE (Sysmex Corporation)
Product Code: SR112023A6047

Market Overview:

The global breast cancer liquid biopsy market size reached US$ 110.7 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 326.2 Million by 2028, exhibiting a growth rate (CAGR) of 17.81% during 2023-2028.

Breast cancer liquid biopsy refers to a non-invasive medical procedure that utilizes blood as a sample for the identification of tumor markers. It assists in evaluating the progression of breast cancer disease and detects Epidermal Growth Factor Receptor (EGFR) gene mutations that help clinicians in choosing the best course of action at the right time. Some of the common biomarkers that are used in this process include circulating tumor cells (CTC), extracellular vesicles, circulating tumor DNA, etc. Breast cancer liquid biopsy offers several benefits, including minimal invasiveness, characterization of new lesions, drug and therapeutic target identifications for cancer treatment, etc.

Breast Cancer Liquid Biopsy Market Trends:

The growing prevalence of breast cancer along with the escalating demand for non-invasive medical procedures is primarily driving the global breast cancer liquid biopsy market. In addition to this, the rising consumer awareness towards numerous benefits associated with the liquid biopsy technique, including quicker results, lower cost, minimal health risk, non-invasiveness, etc., is also augmenting the market growth. Moreover, various global organizations are conducting awareness campaigns to educate individuals about breast health and cancer diagnostic measures. This, in confluence with the increasing number of government and private reimbursement policies for breast cancer biopsy and other related medical procedures, is creating a positive outlook for the market. Apart from this, numerous manufacturers are making significant investments in the introduction of advanced biopsy techniques that enables the enhancement of several aspects of breast cancer management, such as prediction of prognosis, early diagnosis of relapse, serial sampling, efficient longitudinal monitoring of disease progress and response to treatment, etc. Furthermore, the emerging trend of personalized therapeutics coupled with the widespread adoption of polymerase chain reaction (PCR) and next-generation sequencing (NGS) for cancer detection will continue to drive the global breast cancer liquid biopsy market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global breast cancer liquid biopsy market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product services, circulating biomarker and end user.

Breakup by Product Services:

  • Reagent Kits
  • Instruments
  • Services

Breakup by Circulating Biomarker:

  • Circulating Tumor Cells (CTCs)
  • Cell-Free DNA (cfDNA)
  • Extracellular Vesicles (EVs)
  • Others

Breakup by End User:

  • Reference Laboratories
  • Hospitals and Physician Laboratories
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Biocept Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fluxion Biosciences Inc., Guardant Health Inc., Illumina Inc., Menarini Silicon Biosystems (The Menarini Group), NeoGenomics Laboratories Inc., Qiagen and Sysmex Europe SE (Sysmex Corporation).

Key Questions Answered in This Report:

  • What was the size of the global breast cancer liquid biopsy market in 2022?
  • What is the expected growth rate of the global breast cancer liquid biopsy market during 2023-2028?
  • What has been the impact of COVID-19 on the global breast cancer liquid biopsy market?
  • What are the key factors driving the global breast cancer liquid biopsy market?
  • What is the breakup of the global breast cancer liquid biopsy market based on the product services?
  • What are the key regions in the global breast cancer liquid biopsy market?
  • Who are the key players/companies in the global breast cancer liquid biopsy market?

Table of Contents

1   Preface

2   Scope and Methodology

  • 2.1  Objectives of the Study
  • 2.2  Stakeholders
  • 2.3  Data Sources
    • 2.3.1  Primary Sources
    • 2.3.2  Secondary Sources
  • 2.4  Market Estimation
    • 2.4.1  Bottom-Up Approach
    • 2.4.2  Top-Down Approach
  • 2.5  Forecasting Methodology

3   Executive Summary

4   Introduction

  • 4.1  Overview
  • 4.2  Key Industry Trends

5   Global Breast Cancer Liquid Biopsy Market

  • 5.1  Market Overview
  • 5.2  Market Performance
  • 5.3  Impact of COVID-19
  • 5.4  Market Forecast

6   Market Breakup by Product Services

  • 6.1  Reagent Kits
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2  Instruments
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3  Services
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7   Market Breakup by Circulating Biomarker

  • 7.1  Circulating Tumor Cells (CTCs)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2  Cell-Free DNA (cfDNA)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3  Extracellular Vesicles (EVs)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4  Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8   Market Breakup by End User

  • 8.1  Reference Laboratories 
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2  Hospitals and Physician Laboratories
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3  Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9   Market Breakup by Region

  • 9.1  North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2  Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3  Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4  Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5  Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10   SWOT Analysis

  • 10.1  Overview
  • 10.2  Strengths
  • 10.3  Weaknesses
  • 10.4  Opportunities
  • 10.5  Threats

11  Value Chain Analysis

12  Porters Five Forces Analysis

  • 12.1  Overview
  • 12.2  Bargaining Power of Buyers
  • 12.3  Bargaining Power of Suppliers
  • 12.4  Degree of Competition
  • 12.5  Threat of New Entrants
  • 12.6  Threat of Substitutes

13  Price Analysis

14  Competitive Landscape

  • 14.1  Market Structure
  • 14.2  Key Players
  • 14.3  Profiles of Key Players
    • 14.3.1  Biocept Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2  Bio-Rad Laboratories Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3  F. Hoffmann-La Roche AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4  Fluxion Biosciences Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5  Guardant Health Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6  Illumina Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7  Menarini Silicon Biosystems (The Menarini Group)
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8  NeoGenomics Laboratories Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9  Qiagen
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10  Sysmex Europe SE (Sysmex Corporation)
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio

List of Figures

  • Figure 1: Global: Breast Cancer Liquid Biopsy Market: Major Drivers and Challenges
  • Figure 2: Global: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017-2022
  • Figure 3: Global: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 4: Global: Breast Cancer Liquid Biopsy Market: Breakup by Product Services (in %), 2022
  • Figure 5: Global: Breast Cancer Liquid Biopsy Market: Breakup by Circulating Biomarker (in %), 2022
  • Figure 6: Global: Breast Cancer Liquid Biopsy Market: Breakup by End User (in %), 2022
  • Figure 7: Global: Breast Cancer Liquid Biopsy Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Breast Cancer Liquid Biopsy (Reagent Kits) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Breast Cancer Liquid Biopsy (Reagent Kits) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Breast Cancer Liquid Biopsy (Instruments) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Breast Cancer Liquid Biopsy (Instruments) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Breast Cancer Liquid Biopsy (Services) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Breast Cancer Liquid Biopsy (Services) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Breast Cancer Liquid Biopsy (Circulating Tumor Cells (CTCs)) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Breast Cancer Liquid Biopsy (Circulating Tumor Cells (CTCs)) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Breast Cancer Liquid Biopsy (Cell-Free DNA (cfDNA)) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Breast Cancer Liquid Biopsy (Cell-Free DNA (cfDNA)) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Breast Cancer Liquid Biopsy (Extracellular Vesicles (EVs)) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Breast Cancer Liquid Biopsy (Extracellular Vesicles (EVs)) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Breast Cancer Liquid Biopsy (Other Circulating Biomarkers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Breast Cancer Liquid Biopsy (Other Circulating Biomarkers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Breast Cancer Liquid Biopsy (Reference Laboratories) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Breast Cancer Liquid Biopsy (Reference Laboratories) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Breast Cancer Liquid Biopsy (Hospitals and Physician Laboratories) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Breast Cancer Liquid Biopsy (Hospitals and Physician Laboratories) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Breast Cancer Liquid Biopsy (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Breast Cancer Liquid Biopsy (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: North America: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: North America: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: United States: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: United States: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Canada: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Canada: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Asia-Pacific: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Asia-Pacific: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: China: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: China: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Japan: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Japan: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: India: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: India: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: South Korea: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: South Korea: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Australia: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Australia: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Indonesia: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Indonesia: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Others: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Others: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Europe: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Europe: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Germany: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Germany: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: France: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: France: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: United Kingdom: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: United Kingdom: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Italy: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Italy: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Spain: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Spain: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Russia: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Russia: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Others: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Others: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Latin America: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Latin America: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Brazil: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Brazil: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Mexico: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Mexico: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Others: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Others: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Middle East and Africa: Breast Cancer Liquid Biopsy Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Middle East and Africa: Breast Cancer Liquid Biopsy Market: Breakup by Country (in %), 2022
  • Figure 76: Middle East and Africa: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Global: Breast Cancer Liquid Biopsy Industry: SWOT Analysis
  • Figure 78: Global: Breast Cancer Liquid Biopsy Industry: Value Chain Analysis
  • Figure 79: Global: Breast Cancer Liquid Biopsy Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Breast Cancer Liquid Biopsy Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by Product Services (in Million US$), 2023-2028
  • Table 3: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by Circulating Biomarker (in Million US$), 2023-2028
  • Table 4: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 5: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Breast Cancer Liquid Biopsy Market: Competitive Structure
  • Table 7: Global: Breast Cancer Liquid Biopsy Market: Key Players